Objective: To characterize the immunogenicity and the induction of cross-reactive responses against Mycobacterium tuberculosis(M. tuberculosis) of a proteoliposome(PL)from Mycobacterium bovis Bacillus Calmette–Guerin...Objective: To characterize the immunogenicity and the induction of cross-reactive responses against Mycobacterium tuberculosis(M. tuberculosis) of a proteoliposome(PL)from Mycobacterium bovis Bacillus Calmette–Guerin(BCG) with and without alum hydroxide(AL) as adjuvant(PLBCG-AL and PLBCG, respectively) in BALB/c mice.Methods: BALB/c mice were inoculated with phosphate buffer solution, BCG, PLBCG and PLBCG-AL. The humoral immunogenicity was determined by ELISA [immunoglobulin G(Ig G), Ig G1 and Ig G2a] and the cellular immunogenicity was evaluated in vivo by delayed type hypersensitivity. The humoral cross-reactive response against M. tuberculosis was determined by Western blot.Results: Sera from animals immunized with PLBCG-AL and PLBCG showed significant increase in specific total Ig G and Ig G1 antibodies and the presence of cross-reactive antibodies against M. tuberculosis antigens, which were more intense with the use of alum as adjuvant. Mice immunized with PLBCG and PLBCG-AL also showed a specific cellular response in vivo.Conclusions: The cellular and humoral immunogenicity of PLBCG and the capacity to induce cross-reactive responses against M. tuberculosis is in agreement with the protective capacity previously demonstrated by this vaccine candidate and supports the continuation of its evaluation in further stages.展开更多
Liposomes are phospholipid bilayer vesicles,which are biocompatible,biodegradable and nontoxic vehicles suitable for numerous drug and gene delivery applications.In this review,we discuss the prospect of using liposom...Liposomes are phospholipid bilayer vesicles,which are biocompatible,biodegradable and nontoxic vehicles suitable for numerous drug and gene delivery applications.In this review,we discuss the prospect of using liposome technology in the development of a vaccine for tuberculosis.Tuberculosis remains an important health problem that requires the development of an effective vaccine,especially since the only approved vaccine for it continues to be the Bacille Calmette-Geurin(BCG)one developed 100 years ago.This review focuses on the different applications of liposomes toward achieving this goal.Numerous liposomal formulations showing prospect in the research stage and in clinical trials are discussed.展开更多
基金Supported by the Long-Term Research Grant Scheme Grant,Department of Higher Education,Ministry of Education,Malaysia(Grant No.203.PPSK.67212002)as well as the Ministry of Science and Technology,Cuba
文摘Objective: To characterize the immunogenicity and the induction of cross-reactive responses against Mycobacterium tuberculosis(M. tuberculosis) of a proteoliposome(PL)from Mycobacterium bovis Bacillus Calmette–Guerin(BCG) with and without alum hydroxide(AL) as adjuvant(PLBCG-AL and PLBCG, respectively) in BALB/c mice.Methods: BALB/c mice were inoculated with phosphate buffer solution, BCG, PLBCG and PLBCG-AL. The humoral immunogenicity was determined by ELISA [immunoglobulin G(Ig G), Ig G1 and Ig G2a] and the cellular immunogenicity was evaluated in vivo by delayed type hypersensitivity. The humoral cross-reactive response against M. tuberculosis was determined by Western blot.Results: Sera from animals immunized with PLBCG-AL and PLBCG showed significant increase in specific total Ig G and Ig G1 antibodies and the presence of cross-reactive antibodies against M. tuberculosis antigens, which were more intense with the use of alum as adjuvant. Mice immunized with PLBCG and PLBCG-AL also showed a specific cellular response in vivo.Conclusions: The cellular and humoral immunogenicity of PLBCG and the capacity to induce cross-reactive responses against M. tuberculosis is in agreement with the protective capacity previously demonstrated by this vaccine candidate and supports the continuation of its evaluation in further stages.
基金supported by Fundamental Research Grant Scheme (FRGS/1/2018/SKK08/USM/03/1),Ministry of Higher Education (Malaysia)Long-term Research Grant Scheme (LRGS/1/2015/USM/01/1/1),Ministry of Higher Education (Malaysia)
文摘Liposomes are phospholipid bilayer vesicles,which are biocompatible,biodegradable and nontoxic vehicles suitable for numerous drug and gene delivery applications.In this review,we discuss the prospect of using liposome technology in the development of a vaccine for tuberculosis.Tuberculosis remains an important health problem that requires the development of an effective vaccine,especially since the only approved vaccine for it continues to be the Bacille Calmette-Geurin(BCG)one developed 100 years ago.This review focuses on the different applications of liposomes toward achieving this goal.Numerous liposomal formulations showing prospect in the research stage and in clinical trials are discussed.
